Mutations
APP Duplication F028 [MRPL39-APP]
Other Names: ALZ-028 [MRPL39-APP]
Quick Links
Overview
Pathogenicity: Alzheimer's Disease : Pathogenic, Cerebral Amyloid Angiopathy
ACMG/AMP Pathogenicity
Criteria: PS1, PS3, PM1, PM2, PP1
Clinical
Phenotype: Alzheimer's Disease, Cerebral Amyloid Angiopathy
Coding/Non-Coding: Both
DNA
Change: Duplication
Expected RNA
Consequence: Duplication
Expected Protein
Consequence: Duplication
Genomic
Region: Chromosome 21
Findings
This variant is a ~0.6 Mb duplication of a stretch of DNA harboring five genes, from MRPL39 to APP, on chromosome 21. It belongs to the original set of APP duplications first tied to autosomal dominant Alzheimer’s disease (AD) (Rovelet-Lecrux et al., 2006; Cabrejo et al., 2006). The duplication was identified in a French family (F028) with early onset AD and cerebral amyloid angiopathy (CAA). Duplications were detected by analyzing the APP locus on chromosome 21 using quantitative multiplex PCR of short fluorescent fragments (QMPSF)—a method that simultaneously amplifies multiple short genomic sequences. The authors suspected an alteration in this region because AD with CAA is often observed in Down syndrome patients who carry an additional chromosome 21 (see Trisomy 21).
The proband was a man who experienced onset of dementia at age 49 and who died at age 63. His APOE genotype was APOE3/E4. A half-sister, who also carried the duplication and was homozygous for APOE3, had dementia symptoms starting at age 45 and died at age 52. She also had diabetes and dyslipidemia. As is common in carriers of APP duplications, both had seizures that emerged seven years after onset of dementia. The mother of both had dementia starting at age 48, developed seizures three years later, and died at 53. Her carrier status was unknown. None of the affected individuals had intellectual disability or features of Down syndrome before the onset of dementia. Of note, a living sister was a non-carrier and remained healthy at age 61, confirming the duplication segregated with disease.
A subsequent study described the clinical features of three additional maternal half-siblings, including a deceased half-brother with lobar hemorrhage, a deceased half-brother with dementia and seizures, and a deceased half-sister with seizures and stroke (Grangeon et al., 2023).
APP duplications are rare or absent from the general population (Sharp et al., 2005) and appear to be a rare cause of early onset AD (e.g., Hooli et al., 2012; June 2013 news; Wang et al., 2023).
Neuropathology
Neuropathology in the proband and his half-sister was consistent with AD, with abundant amyloid deposits, including dense-core plaque and diffuse deposits, and neurofibrillary tangles in the hippocampal cortex, the limbic system, and the isocortex (Cabrejo et al., 2006; Rovelet-Lecrux et al., 2006; Grangeon et al., 2023). In addition, severe cerebral amyloid angiopathy was extensive. Focal areas of demyelination were seen around most blood vessels. Vascular amyloid was predominantly composed of Aβ40.
Moreover, MRI imaging of the half-sister’s brain disclosed white matter changes in the frontal cortex and the parieto-occipital cortex, where they were severe. Atrophy was seen in the temporal and parieto-occipital cortices, as well as, to a lower extent, in the left frontal cortex.
Biological Effect
The biological effect of this specific APP duplication is unknown, but a study of multiple carriers of APP duplications showed that, as expected, the median levels of APP mRNA in blood were approximately 1.4-fold higher in carriers compared with non-carriers (Pottier et al., 2012). However, variability between duplications and individual carriers suggests other factors, such as the specific genes included in the duplication, may modulate expression (e.g., Lott and Head, 2019).
Of note, APP is in a recombination hotspot harboring multiple low copy repeats that may facilitate APP duplication (Sleegers et al., 2006; Rovelet-Lecrux et al., 2006).
Pathogenicity
Alzheimer's Disease : Pathogenic
This variant fulfilled the following criteria based on the ACMG/AMP guidelines. See a full list of the criteria in the Methods page.
PS1-M
Same amino acid change as a previously established pathogenic variant regardless of nucleotide change. Duplication F028 [MRPL39-APP]: Similar to other APP duplications known to be pathogenic, although exact DNA changes varied.
PS3-M
Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product. Duplication F028 [MRPL39-APP]: Data unavailable for this specific duplication, but pooled data reveal APP duplications increase APP dosage.
PM1-S
Located in a mutational hot spot and/or critical and well-established functional domain (e.g. active site of an enzyme) without benign variation. Duplication F028 [MRPL39-APP]: Mutation encompasses the APP gene, a mutational hotspot and a gene known to play a well-established functional role in AD.
PM2-M
Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium. *Alzforum uses the gnomAD variant database.
PP1-M
Co-segregation with disease in multiple affected family members in a gene definitively known to cause the disease: *Alzforum requires at least one affected carrier and one unaffected non-carrier from the same family to fulfill this criterion.
Pathogenic (PS, PM, PP) | Benign (BA, BS, BP) | |||||
---|---|---|---|---|---|---|
Criteria Weighting | Strong (-S) | Moderate (-M) | Supporting (-P) | Supporting (-P) | Strong (-S) | Strongest (BA) |
Last Updated: 13 Jul 2023
References
Mutations Citations
News Citations
Paper Citations
- Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerrière A, Vital A, Dumanchin C, Feuillette S, Brice A, Vercelletto M, Dubas F, Frebourg T, Campion D. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet. 2006 Jan;38(1):24-6. Epub 2005 Dec 20 PubMed.
- Cabrejo L, Guyant-Maréchal L, Laquerrière A, Vercelletto M, De la Fournière F, Thomas-Antérion C, Verny C, Letournel F, Pasquier F, Vital A, Checler F, Frebourg T, Campion D, Hannequin D. Phenotype associated with APP duplication in five families. Brain. 2006 Nov;129(Pt 11):2966-76. Epub 2006 Sep 7 PubMed.
- Grangeon L, Charbonnier C, Zarea A, Rousseau S, Rovelet-Lecrux A, Bendetowicz D, Lemaitre M, Malrain C, Quillard-Muraine M, Cassinari K, Maltete D, Pariente J, Moreaud O, Magnin E, Cretin B, Mackowiak MA, Sillaire AR, Vercelletto M, Dionet E, Felician O, Rod-Olivieri P, Thomas-Antérion C, Godeneche G, Sauvée M, Cartz-Piver L, Le Ber I, Chauvire V, Jonveaux T, Balageas AC, Laquerriere A, Duyckaerts C, Vital A, de Paula AM, Meyronet D, Guyant-Marechal L, Hannequin D, Tournier-Lasserve E, Campion D, CNR-MAJ collaborators, Nicolas G, Wallon D. Phenotype and imaging features associated with APP duplications. Alzheimers Res Ther. 2023 May 11;15(1):93. PubMed.
- Sharp AJ, Locke DP, McGrath SD, Cheng Z, Bailey JA, Vallente RU, Pertz LM, Clark RA, Schwartz S, Segraves R, Oseroff VV, Albertson DG, Pinkel D, Eichler EE. Segmental duplications and copy-number variation in the human genome. Am J Hum Genet. 2005 Jul;77(1):78-88. Epub 2005 May 25 PubMed.
- Hooli BV, Mohapatra G, Mattheisen M, Parrado AR, Roehr JT, Shen Y, Gusella JF, Moir R, Saunders AJ, Lange C, Tanzi RE, Bertram L. Role of common and rare APP DNA sequence variants in Alzheimer disease. Neurology. 2012 Apr 17;78(16):1250-7. Epub 2012 Apr 4 PubMed.
- Wang H, Dombroski BA, Cheng P-L, Tucci A, Si Y-q, Farrell JJ, Tzeng J-Y, Leung YY, Malamon JS, Wang L-S, Vardarajan BN, Farrer LA, Schellenberg GD, Lee W-P. Structural Variation Detection and Association Analysis of Whole-Genome-Sequence Data from 16,905 Alzheimer's Diseases Sequencing Project Subjects. 2023 Sep 13 10.1101/2023.09.13.23295505 (version 1) medRxiv.
- Pottier C, Wallon D, Lecrux AR, Maltete D, Bombois S, Jurici S, Frebourg T, Hannequin D, Campion D. Amyloid-β protein precursor gene expression in alzheimer's disease and other conditions. J Alzheimers Dis. 2012;28(3):561-6. PubMed.
- Lott IT, Head E. Dementia in Down syndrome: unique insights for Alzheimer disease research. Nat Rev Neurol. 2019 Mar;15(3):135-147. PubMed.
- Sleegers K, Brouwers N, Gijselinck I, Theuns J, Goossens D, Wauters J, Del-Favero J, Cruts M, van Duijn CM, Van Broeckhoven C. APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. Brain. 2006 Nov;129(Pt 11):2977-83. Epub 2006 Aug 18 PubMed.
Further Reading
No Available Further Reading
Protein Diagram
Primary Papers
- Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerrière A, Vital A, Dumanchin C, Feuillette S, Brice A, Vercelletto M, Dubas F, Frebourg T, Campion D. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet. 2006 Jan;38(1):24-6. Epub 2005 Dec 20 PubMed.
Other mutations at this position
- APP Duplication 1104 [APP-APP]
- APP Duplication ALZ-254 [POTED-ADAMTS5]
- APP Duplication ALZ-478 [LINC00158-EIF4A1P]
- APP Duplication EXT 1853 [MRPL39-CYYR1]
- APP Duplication EXT 2066 [MRPL39-APP]
- APP Duplication EXT-006 [HSPA13-GRIK1]
- APP Duplication EXT-019 [LINC00158-USP16]
- APP Duplication EXT-054 [USP25-ADAMTS1]
- APP Duplication EXT-1093 [AK124194-CYYR1]
- APP Duplication EXT-1230 [BTG3- ADAMTS5]
- APP Duplication EXT-1252 [LINC00158-ADAMTS1]
- APP Duplication EXT-144 [BTG3-EIF4A1P]
- APP Duplication EXT-145 [NCAM2-EIF4A1P]
- APP Duplication EXT-1516 [APP-ADAMTS1]
- APP Duplication EXT-1864 [TUBAP-ADAMTS1]
- APP Duplication EXT-187 [POTED-ADAMTS5]
- APP Duplication EXT-262 [JAM2-APP]
- APP Duplication EXT-279 [GABPA-ADAMTS1]
- APP Duplication EXT-298 [GABPA-CYYR1]
- APP Duplication EXT-773 [LINC00158-CYYR1]
- APP Duplication EXT-814 [NCAM2-ADAMTS5]
- APP Duplication EXT-857 [MRPL39-ADAMTS5]
- APP Duplication F009 [LINC00158-EIF4A1P]
- APP Duplication F019 [LINC00158-BACH1]
- APP Duplication F037 [LINC00158-APP]
- APP Duplication F229 [NCAM2-EIF4A1P]
- APP Duplication PED 2945 [APP-CYYR1]
- APP Duplication PED 3281 [LINC00158-ADAMTS5]
- APP Duplication [APP-CYYR1]
- APP Duplication [JAM2-APP]
- APP Triplication [APP-APP]
Disclaimer: Alzforum does not provide medical advice. The Content is for informational, educational, research and reference purposes only and is not intended to substitute for professional medical advice, diagnosis or treatment. Always seek advice from a qualified physician or health care professional about any medical concern, and do not disregard professional medical advice because of anything you may read on Alzforum.
Comments
Inserm
A great discovery. I agree with John Hardy that this discovery shows, once and for all, the major role of APP dysfunction n Alzheimer disease.
At first sight, the paper strongly reinforces the amyloid cascade hypothesis. However, in these familial cases, like in all other familial and sporadic AD cases, dementia occurs with a neocortical tauopathy, showing also that AD explanation is more likely an APP-tau deleterious interaction.
View all comments by Andre DelacourteThe role of copy number polymorphisms in human genetic variation has only recently been appreciated and only investigated in a few diseases. This provides the first evidence that gene copy number abberations, in addition to being a mechanism of Parkinson disease, can be a cause of AD. So, the discovery about a decade ago of the CMT duplication may have been just the tip of the iceberg.
View all comments by Daniel GeschwindMake a Comment
To make a comment you must login or register.